April Sykes1, Elsie Gerhardt2, Li Tang1, Elisabeth E Adderson3. 1. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN. 2. Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN. 3. Department of Infectious Diseases, St. Jude Children's Research Hospital, Carmel, IN; Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN. Electronic address: elisabeth.adderson@stjude.org.
Abstract
OBJECTIVE: The objective of this study was to determine the effectiveness of trivalent inactivated influenza vaccine (TIV) for the prevention of laboratory-confirmed influenza and influenza-like illnesses (ILI) among children and adolescents receiving therapy for acute leukemia. STUDY DESIGN: A retrospective review of the demographic and clinical characteristics of 498 patients at a pediatric cancer center who received therapy for acute leukemia during 3 successive influenza seasons (2010-2011 through 2012-2013). RESULTS: In 498 patient seasons with a known immunization history (median age, 6 years; range, 1-21), 354 patients (71.1%) were immunized with TIV and 98 (19.7%) received a booster dose of vaccine. Vaccinated and unvaccinated patients had generally similar demographic characteristics. There were no differences in the overall rates of influenza or ILI between vaccinated and unvaccinated patients overall, or in any individual season. There was no difference in the rates of influenza or ILI between patients who received 1 dose of vaccine and those who received 2 doses. Time to first influenza infection and time to first ILI in vaccinated and unvaccinated patients were not different. CONCLUSION: TIV did not protect children and adolescents with acute leukemia against laboratory-confirmed influenza or ILI. Future prospective studies should assess TIV effectiveness in high-risk subpopulations and alternative strategies to prevent influenza should be considered in this population.
OBJECTIVE: The objective of this study was to determine the effectiveness of trivalent inactivated influenza vaccine (TIV) for the prevention of laboratory-confirmed influenza and influenza-like illnesses (ILI) among children and adolescents receiving therapy for acute leukemia. STUDY DESIGN: A retrospective review of the demographic and clinical characteristics of 498 patients at a pediatric cancer center who received therapy for acute leukemia during 3 successive influenza seasons (2010-2011 through 2012-2013). RESULTS: In 498 patient seasons with a known immunization history (median age, 6 years; range, 1-21), 354 patients (71.1%) were immunized with TIV and 98 (19.7%) received a booster dose of vaccine. Vaccinated and unvaccinated patients had generally similar demographic characteristics. There were no differences in the overall rates of influenza or ILI between vaccinated and unvaccinated patients overall, or in any individual season. There was no difference in the rates of influenza or ILI between patients who received 1 dose of vaccine and those who received 2 doses. Time to first influenza infection and time to first ILI in vaccinated and unvaccinated patients were not different. CONCLUSION:TIV did not protect children and adolescents with acute leukemia against laboratory-confirmed influenza or ILI. Future prospective studies should assess TIV effectiveness in high-risk subpopulations and alternative strategies to prevent influenza should be considered in this population.
Authors: Steven Black; Uwe Nicolay; Timo Vesikari; Markus Knuf; Giuseppe Del Giudice; Giovanni Della Cioppa; Theodore Tsai; Ralf Clemens; Rino Rappuoli Journal: Pediatr Infect Dis J Date: 2011-12 Impact factor: 2.129
Authors: A Kempe; C B Hall; N E MacDonald; H R Foye; K A Woodin; H J Cohen; E D Lewis; M Gullace; C L Gala; C S Dulberg; E Katsanis Journal: J Pediatr Date: 1989-07 Impact factor: 4.406
Authors: Gábor Ottóffy; Petra Horváth; Lajos Muth; Alexander Sólyom; Miklós Garami; Gábor Kovács; Tibor Nyári; Dénes Molnár; Gábor Pauler; István Jankovics Journal: Pediatr Blood Cancer Date: 2014-01-03 Impact factor: 3.167
Authors: Mark G Thompson; Allison Naleway; Alicia M Fry; Sarah Ball; Sarah M Spencer; Sue Reynolds; Sam Bozeman; Min Levine; Jacqueline M Katz; Manjusha Gaglani Journal: Vaccine Date: 2016-02-10 Impact factor: 3.641
Authors: Helen E Quinn; Thomas L Snelling; Andrew Habig; Clayton Chiu; Paula J Spokes; Peter B McIntyre Journal: Pediatrics Date: 2014-09-15 Impact factor: 7.124
Authors: Mei Shang; Jessie R Chung; Michael L Jackson; Lisa A Jackson; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard K Zimmerman; Mary Patricia Nowalk; Alicia M Fry; Brendan Flannery Journal: Vaccine Date: 2018-11-09 Impact factor: 3.641
Authors: Marcela V Maus; Sara Alexander; Michael R Bishop; Jennifer N Brudno; Colleen Callahan; Marco L Davila; Claudia Diamonte; Jorg Dietrich; Julie C Fitzgerald; Matthew J Frigault; Terry J Fry; Jennifer L Holter-Chakrabarty; Krishna V Komanduri; Daniel W Lee; Frederick L Locke; Shannon L Maude; Philip L McCarthy; Elena Mead; Sattva S Neelapu; Tomas G Neilan; Bianca D Santomasso; Elizabeth J Shpall; David T Teachey; Cameron J Turtle; Tom Whitehead; Stephan A Grupp Journal: J Immunother Cancer Date: 2020-12 Impact factor: 13.751